Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback